About Matthew Stanton
Matthew Stanton, PhD, is CEO and a board director of Typewriter Therapeutics. He was earlier chief scientific officer of Generation Bio and head of chemistry at Moderna, where his team discovered SM-102, the key lipid in the Spikevax COVID-19 vaccine.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Matthew Stanton in the role, so the role may have started earlier or lasted longer.
Typewriter Therapeutics, Inc. Current
Chief Executive Officer and Board Director
2026 – Present · Cambridge, MA
Typewriter Therapeutics develops all-RNA medicines that insert a full working gene at a natural safe harbor site in the genome, starting with in vivo CAR-T.
RI
Raven (RA Capital's incubator)
Venture Partner
GB
Generation Bio
Chief Scientific Officer
Chief Technology Officer
MT
Moderna Therapeutics
Vice President and Head of Chemistry
ME
Merck
Head of siRNA Chemistry
Education
- PhD, University of North Carolina at Chapel Hill
- Bachelor's degree, Virginia Tech
Key Colleagues at Startups
The people Matthew Stanton works with at each company, as listed on that company's latest Form D.
Typewriter Therapeutics, Inc. · Form D, Sep 21, 2026